The impact of IDAC consolidation on survival in AML patients with and without gene mutations were analyzed and found that AML patients harboring FLT3-ITD and both FLT3-ITD and NPM1 mutations had poor RFS and OS compared with those in AML patients with mutant NPM1 or no mutated gene (Fig. 5). The gene discussed is FLT3; the disease is acute myeloid leukemia.